H
Hirokazu Okada
Researcher at Saitama Medical University
Publications - 124
Citations - 3017
Hirokazu Okada is an academic researcher from Saitama Medical University. The author has contributed to research in topics: Kidney disease & Renal function. The author has an hindex of 25, co-authored 106 publications receiving 2450 citations.
Papers
More filters
Journal ArticleDOI
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin
Atsuhiro Ichihara,Matsuhiko Hayashi,Yuki Kaneshiro,Fumiaki Suzuki,Tsutomu Nakagawa,Yuko Tada,Yukako Koura,Akira Nishiyama,Hirokazu Okada,M. Nasir Uddin,A.H.M. Nurun Nabi,Yuichi Ishida,Tadashi Inagami,Takao Saruta +13 more
TL;DR: It is proposed that the nonproteolytic activation of prorenin may be a significant mechanism of diabetic nephropathy and the mechanism and substances causing non Prorenin activation may serve as important therapeutic targets for the prevention of diabetic organ damage.
Journal ArticleDOI
FAT is a component of glomerular slit diaphragms.
Tsutomu Inoue,Eishin Yaoita,Hidetake Kurihara,Fujio Shimizu,Tatsuo Sakai,Tatsuya Kobayashi,Kazufumi Ohshiro,Hiroshi Kawachi,Hirokazu Okada,Hiromichi Suzuki,Itaru Kihara,Tadashi Yamamoto +11 more
TL;DR: The molecular structure of FAT and its colocalization with 5-1-6 antigen and ZO-1 indicate that FAT is a component of slit diaphragms.
Journal ArticleDOI
Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Christopher T. Chan,Peter J. Blankestijn,Laura M. Dember,Maurizio Gallieni,David Harris,Charmaine E. Lok,Rajnish Mehrotra,Paul E. Stevens,Angela Yee-Moon Wang,Michael Cheung,David C. Wheeler,Wolfgang C. Winkelmayer,Carol A. Pollock,Ali K. Abu-Alfa,Joanne M. Bargman,Anthony J. Bleyer,Edwina A. Brown,Andrew Davenport,Simon J. Davies,Frederic O. Finkelstein,Jennifer E. Flythe,Eric Goffin,Thomas A. Golper,Rafael Gomez,Takayuki Hamano,Manfred Hecking,Olof Heimbürger,Barnaby Hole,Daljit Hothi,T. Alp Ikizler,Yoshitaka Isaka,Kunitoshi Iseki,Vivekanand Jha,Hideki Kawanishi,Peter G. Kerr,Paul Komenda,Csaba P. Kovesdy,Ed Lacson,Maurice Laville,Jung Pyo Lee,Edgar V. Lerma,Nathan W. Levin,Monika Lichodziejewska-Niemierko,Adrian Liew,Elizabeth Lindley,Robert S. Lockridge,Magdalena Madero,Ziad A. Massy,Linda M. McCann,Klemens B. Meyer,Rachael L. Morton,Annie Claire Nadeau-Fredette,Hirokazu Okada,José Pérez,Jeff Perl,Kevan R. Polkinghorne,Miguel C. Riella,Bruce M. Robinson,Michael V. Rocco,Steven J. Rosansky,Joris I. Rotmans,María Fernanda Slon Roblero,Navdeep Tangri,Marcello Tonelli,Allison Tong,Yusuke Tsukamoto,Kriang Tungsanga,Tushar J. Vachharajani,Ismay van Loon,Suzanne Watnick,Daniel E. Weiner,Martin Wilkie,Elena Zakharova +72 more
TL;DR: The need to move away from a "one-size-fits-all" approach to dialysis and provide more individualized care that incorporates patient goals and preferences while still maintaining best practices for quality and safety is represented during the KDIGO conference.
Journal ArticleDOI
Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.
TL;DR: In patients with hypertension starting CAPD therapy, valsartan slows the decline in residual renal function and contributes to maintenance of weekly creatinine clearance and Kt/V (fraction per dialysis), which are the major factors contributing to the mortality and morbidity of CAPD patients.
Journal ArticleDOI
Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis.
Hironori Nemoto,Hidetomo Nakamoto,Hirokazu Okada,Souichi Sugahara,Kenshi Moriwaki,Mitsuru Arai,Yoshihiko Kanno,Hiromichi Suzuki +7 more
TL;DR: It is concluded that treatment with PMX-F in patients with sepsis is effective and prolongs the survival rate when applied at an early stage of septicaemia, however, in severe sepsi, this therapy does not improve the survival rates.